Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (291-300 of 502) with videos related to

Pageof 51
Sort By:
Cancer Medicine|May 24, 2022
Impact of concomitant fibrates on immunotherapy outcomes for advanced non-small cell lung cancerWilliam A Stokes, Madhusmita Behera, Renjian Jiang, et al.
Oncology|June 19, 2018
Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I TrialsTaofeek K Owonikoko, Adeniyi K Busari, Sungjin Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2013
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)S Ramalingam, J Crawford, A Chang, et al.
JTO Clinical and Research Reports|January 22, 2026
Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery DataMadhusmita Behera, Gregory Joseph, Manali Rupji, et al.
Future Oncology (London, England)|December 17, 2021
Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study designGregory J Riely, Myung-Ju Ahn, Enriqueta Felip, et al.
The Oncologist|September 25, 2024
The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitorsNikhil T Sebastian, William A Stokes, Madhusmita Behera, et al.
Advances in Therapy|March 2, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 TrialHorst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall, et al.
JTO Clinical and Research Reports|September 30, 2021
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)Rathi N Pillai, Suresh S Ramalingam, Meena Thayu, et al.
Clinical Lung Cancer|February 22, 2023
The Association of Improved Overall Survival with NSAIDs in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint InhibitorsNikhil T Sebastian, William A Stokes, Madhusmita Behera, et al.
Cancer|June 17, 2025
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161Ticiana A Leal, Yating Wang, Afshin Dowlati, et al.
Pageof 51

Showing results (291-300 of 502) with videos related to

Sort By:
Pageof 51
Cancer Medicine|May 24, 2022
Impact of concomitant fibrates on immunotherapy outcomes for advanced non-small cell lung cancerWilliam A Stokes, Madhusmita Behera, Renjian Jiang, et al.
Oncology|June 19, 2018
Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I TrialsTaofeek K Owonikoko, Adeniyi K Busari, Sungjin Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2013
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)S Ramalingam, J Crawford, A Chang, et al.
JTO Clinical and Research Reports|January 22, 2026
Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery DataMadhusmita Behera, Gregory Joseph, Manali Rupji, et al.
Future Oncology (London, England)|December 17, 2021
Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study designGregory J Riely, Myung-Ju Ahn, Enriqueta Felip, et al.
The Oncologist|September 25, 2024
The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitorsNikhil T Sebastian, William A Stokes, Madhusmita Behera, et al.
Advances in Therapy|March 2, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 TrialHorst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall, et al.
JTO Clinical and Research Reports|September 30, 2021
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)Rathi N Pillai, Suresh S Ramalingam, Meena Thayu, et al.
Clinical Lung Cancer|February 22, 2023
The Association of Improved Overall Survival with NSAIDs in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint InhibitorsNikhil T Sebastian, William A Stokes, Madhusmita Behera, et al.
Cancer|June 17, 2025
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161Ticiana A Leal, Yating Wang, Afshin Dowlati, et al.
Pageof 51